Toshiyuki Tahara

Utsunomiya, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Real-world efficacy and safety of avatrombopag in Japanese patients with chronic liver disease and severe thrombocytopenia.

Real-world efficacy and safety of avatrombopag in Japanese patients with chronic liver disease and severe thrombocytopenia.

Journal: Journal of gastroenterology

Published: March 31, 2026

Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study.

Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 16, 2026

Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a multicenter cohort study.

Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a multicenter cohort study.

Journal: Frontiers in immunology

Published: June 25, 2025

Three-year outcomes under pemafibrate therapy in patients with metabolic dysfunction-associated steatotic liver disease: a long-term observational study.

Three-year outcomes under pemafibrate therapy in patients with metabolic dysfunction-associated steatotic liver disease: a long-term observational study.

Journal: Clinical and experimental hepatology

Published: February 19, 2025

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose.

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose.

Journal: Metabolites

Published: January 14, 2025

Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective Study.

Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective Study.

Journal: Journal of gastroenterology and hepatology

Published: September 19, 2024

The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study.

The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study.

Journal: Intestinal research

Published: August 09, 2024

Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study.

Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study.

Journal: Intestinal research

Published: May 01, 2024

Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study.

Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study.

Journal: Intestinal research

Published: April 09, 2024

Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.

Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.

Journal: Journal of gastroenterology

Published: November 29, 2023

Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study.

Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study.

Journal: Life (Basel, Switzerland)

Published: April 12, 2023

Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients.

Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients.

Journal: Clinical and experimental hepatology

Published: July 02, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026